$REPL news
The latest REPL stock news: headlines, filings, AI summaries and sentiment for $REPL, updated around the clock.
- Replimune Group, Inc. - 10-Q Filing
- Replimune Announces Commercial Launch of TUDRIQEV for Advanced Melanoma
- Replimune Reports Q2 2026 Financial Results and Commencement of TUDRIQEV Commercial Shipments
- Replimune Anticipates Permanent J-code for TUDRIQEV by April 2027
- Replimune Group, Inc. - 10-Q Filing
- Replimune Group, Inc. - 8-K Filing
- Replimune Group, Inc. - 8-K Filing
- Class Action Lawsuit Filed Against Replimune Group, Inc.
- Class Action Lawsuit Filed Against Replimune Group Following FDA's BLA Denial
- Stocks Making Significant Moves Midday: IES Holdings, GoDaddy, and Others
- Roblox Downgraded, Quanta Services Upgraded: Key Analyst Calls
- Premarket Stock Movements: Replimune Surges Over 130%, Amazon Rises More Than 11%
- Replimune Group, Inc. - 8-K Filing
- Replimune Shares Rise Following Positive FDA Advisory Committee Vote
- Replimune Group, Inc. - 8-K Filing
- Replimune Group, Inc. - 10-K Filing
- Replimune Group, Inc. - 8-K Filing
- Replimune's Lead Drug Accepted for FDA Review
- Replimune Group, Inc. - 8-K Filing
- Replica and Arity Launch Safety Hub Platform for Roadway Risk Reduction
- Replimune Gains FDA Approval Submission After White House Intervention
- Investor Alert: Pomerantz Law Firm Investigates Replimune Group for Potential Securities Fraud
- Pomerantz Law Firm Investigates Replimune Group for Potential Securities Fraud
- FDA Commissioner Defends Drug Approval Decisions Amid Backlash
- Pomerantz Law Firm Investigates Replimune Group, Inc. for Potential Securities Fraud
- Jefferies Downgrades Replimune Group (REPL) After FDA Decision Creates Uncertainty
- Replimune Faces Major Setback After FDA Rejects Lead Cancer Therapy for Second Time
- Replimune's Melanoma Therapy Rejected by FDA, Shares Drop Sharply
- Replimune Faces Major Setback After FDA Rejects Cancer Therapy Again